Magenta therapeutics and avrobio collaborate to evaluate targeted antibody-drug conjugate

Magenta therapeutics and avrobio announce collaboration to evaluate targeted antibody-drug conjugate as a potential conditioning regimen for lentiviral gene therapies.magenta therapeutics inc - co & avrobio will jointly evaluate mgta-117 in conjunction with one or more of avrobio's investigational gene therapies.magenta therapeutics - under collaboration, each company will retain all commercial rights to their respective programs.magenta therapeutics inc - magenta will retain all commercial rights to mgta-117.magenta therapeutics -avrobio will retain all commercial rights to its gene therapies.magenta therapeutics - avrobio will be responsible for clinical trial costs related to evaluation of mgta-117 with avrobio's gene therapies.
DNTH Ratings Summary
DNTH Quant Ranking